I-Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Incazelo emfushane:

Igama Lekhemikhali: Lasofoxifene Tartrate

CAS: 190791-29-8

Ukubukeka: Impushana Emhlophe ukuya Emhlophe

Ukuhlanzeka kweChiral: ≥99.0%Ubumsulwa: ≥98.0% (HPLC)

Ekwelapheni i-Postmenopausal Osteoporosis

Ikhwalithi ephezulu ye-API, Ukukhiqiza Kwezentengiso

Inquiry: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Ukunikezela Komkhiqizi Ngokuhlanzeka Okuphezulu kanye Nekhwalithi Ezinzile
Igama Lekhemikhali: Lasofoxifene Tartrate
CAS: 190791-29-8
I-Lasofoxifene Tartrate (CAS: 190791-29-8) ekwelapheni i-Postmenopausal Osteoporosis

Chemical Properties:

Igama Lekhemikhali	I-Lasofoxifene Tartrate
Omqondofana	(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl) ethoxy]phenyl]-2-naphthalenol Tartrate Oporia
Inombolo ye-CAS	190791-29-8
Inombolo yeCAT	I-RF-API20
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifika Emakhulwini Amakhilogremu
I-Molecular Formula	I-C28H31NO2.ClH
Isisindo samangqamuzana	450.019
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	Impushana Emhlophe Kuya Kumhlophe
Umswakama (KF)	≤0.50%
Izinsimbi Ezisindayo	≤20ppm
I-Chiral Purity	≥99.0%
Ukuhlanzeka / Indlela Yokuhlaziya	≥98.0% (HPLC)
Ukulahlekelwa Ekumisweni	≤0.50%
Izinsalela ekushiseni	≤0.50%
Izinga Lokuhlola	I-Chinese Pharmacopoeia (CP);I-Enterprise Standard
Ukusetshenziswa	I-Active Pharmaceutical Ingredient (API);I-Postmenopausal Osteoporosis

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, isigubhu seCardboard, 25kg/Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni, umswakama kanye nezinambuzane.

Izinzuzo:

I-FAQ:

Isicelo:

I-Shanghai Ruifu Chemical Co., Ltd. ingumkhiqizi oholayo kanye nomphakeli we-Lasofoxifene Tartrate (CAS: 190791-29-8) enekhwalithi ephezulu.
I-Lasofoxifene Tartrate iyisizukulwane sesithathu, i-non-steroidal selective estrogen receptor modulator (SERM).Ibophezela ngokukhetha ku-ERalpha yomuntu enenani le-IC50 le-1.5 nM futhi ivimbela ukulahleka kwamathambo kumagundane aphethwe yi-ovariectomized.Ezifundweni zomtholampilo ze-postmenopausal osteoporosis, i-0.5 mg / ngosuku i-lasofoxifene yayihlotshaniswa nezingozi ezincishisiwe ze-nonvertebral kanye ne-vertebral fractures, umdlavuza webele we-ER-positive, isifo senhliziyo, kanye nesifo sohlangothi kodwa ingozi eyengeziwe yezenzakalo ze-venous thromboembolic.I-Lasofoxifene nayo ikhonjiswe ukuthi isebenze njenge-agonist ephambene ku-CB2 cannabinoid receptor, okubonisa amandla ayo okuphinda asetshenziswe njengendlela yokwelapha yezinkomba lapho i-CB2 ihloselwe khona.